PH46A,
belonging to a class of 1,2-Indane dimers, has been developed
by our research group as a potential therapeutic agent for the treatment
of inflammatory and autoimmune diseases. The initial synthetic route
to PH46A gave a low overall yield, due in large part to the generation
of undesired diastereoisomer 5 and the unwanted enantiomer
(R,R)-8 during the
synthesis. The aim of this work was to carry out a comprehensive investigation
into the stereoselective synthesis of PH46A. Significant progress
was made on the ketone reduction step, where the use of triisobutylaluminum
[TiBA, Al(iBu)3] afforded high selectivity for the target
diastereoisomer (rac)-6, compared to
the unfavorable ratio obtained using a previous process. This enabled
a multikilo scale synthesis of PH46A in a GMP environment. Further,
a brief proof-of-principle investigation was carried out using an
achiral phase transfer catalyst (PTC) for alkylation at the methine
carbon of the parent indanone.